Abstract 1353P
Background
TP53 variants are common in NSCLC and have been reported as predictive of response and prognostic of poor outcome in EGFR-mutant NSCLC. The impact of TP53 co-mutation in NSCLCs carrying rarer driver mutations with approved targeted treatments is unclear.
Methods
Records of 236 patients with rare driver mutation positive NSCLC at Princess Margaret Cancer Centre were reviewed. Associations between TP53 status, baseline demographics and outcomes (response [ORR], survival [OS], progression-free survival [PFS]), were investigated. ORR (to first-line targeted therapy only) was compared via Fisher’s exact test. OS and PFS were compared by Kaplan-Meier estimates, and Cox regression adjusted for stage at diagnosis with wildtype (WT) as reference.
Results
TP53 variants were found in 88/236 (37%; table) with two+ driver mutations in 22 (9%). There were no significant demographic differences between TP53-mutated (MUT) and WT except for smoking status (never smokers 58% TP53-MUT v 70% TP53-WT, p=0.002). ORR to first-line targeted treatment was 54% vs 71% in the TP53-MUT and WT cohorts, respectively (p=0.09). More patients with TP53-MUT cancer had progressive disease (PD) as best response (27% v 8%, p=0.005). Median PFS was 19.6 mos for TP53-MUT (95% CI 14.4-24.3) v 42.7 mos for WT (CI 31-72.9) (stage-adjusted hazard ratio (aHR) 2.35, CI 1.62-3.39; p<0.001). Median OS was significantly shorter in the TP53-MUT cohort at 20.9 mos (CI 17.3-30.7) compared to 66.4 mos (CI 54.8-not reached) (aHR 3.30, CI 2.20-4.95; p<0.001). In a subset with fusion mutations (ALK, ROS1, RET, NRG1), we saw similar trends in ORR (67% TP53-MUT v 88% WT, p=0.11), PFS (aHR 2.83, CI 1.52-5.27; p=0.001), and OS (aHR 5.00, CI 2.42-10.33; p<0.001). Table: 1353P
TP53 wildtype (n=148) N (%) | TP53 mutated (n=88) N (%) | p value | |
Median age (range) | 62.1 (31.8, 91.0) | 64.8 (22.0, 90.0) | 0.40 |
Female sex | 91 (61%) | 49 (56%) | 0.46 |
Never smoker | 99 (70%) | 49 (58%) | 0.06 |
Adenocarcinoma | 141 (95%) | 83 (94%) | 0.99 |
Stage at diagnosis I/II III IV | 32 (22%) 31 (21%) 85 (57%) | 16 (18%) 15 (17%) 57 (65%) | 0.54 |
Brain metastases at any time | 49 (36%) | 31 (37%) | 0.90 |
Driver mutations ALK BRAF V600E EGFR exon 20 ins Uncommon EGFR HER2 exon 20 ins HER2 oncogenic SNV KIT MET exon 14 skip NRG1 RET ROS1 Multiple | 44 6 3 3 27 4 0 18 2 10 15 16 | 9 1 5 3 21 6 1 17 0 6 8 11 | |
Response to first line targeted treatment CR PR SD PD Non-evaluable | n=100 1 (1%) 64 (65%) 19 (19%) 8 (8%) 8 (7%) | n=49 0 22 (45%) 6 (12%) 13 (27%) 8 (14%) | 0.005 |
Conclusions
TP53 co-mutation with multiple rare driver mutations is predictive of poor response to targeted treatments and prognostic of shorter OS and PFS in NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Feng: Financial Interests, Personal, Invited Speaker: AstraZeneca. N. Leighl: Financial Interests, Personal, Other, CME/independent lectures: MSD, BMS, Hoffmann LaRoche, EMD Serono; Financial Interests, Personal, Invited Speaker, independent lectures: Novartis, Takeda; Financial Interests, Personal, Advisory Board: Puma Biotechnology; Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, Array, Bayer, EMD Serono, Guardant Health, Lilly, MSD, Pfizer, Roche, Takeda, Janssen. G. Liu: Financial Interests, Personal, Advisory Board: Takeda, AstraZeneca, Pfizer, Lilly, Merck, Novartis, Jazz, Bristol Myers Squibb, EMD Serono; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim, Takeda, AstraZeneca, EMD Serono. P. Bradbury: Financial Interests, Personal, Advisory Role: Merck, AbbVie, Eli Lilly, Pfizer, Boehringer Ingelheim; Non-Financial Interests, Personal, Advisory Board: Mirati, AstraZeneca. A. Sacher: Financial Interests, Institutional, Coordinating PI: Genentech-Roche, BMS, AstraZeneca; Financial Interests, Institutional, Local PI: Amgen, Iovance, CRISPR Therapeutics, Merck, Pfizer, GSK, Spectrum, Lilly. F.A. Shepherd: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Local PI: AstraZeneca, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1037P - Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors
Presenter: Nicolas Mach
Session: Poster session 19
1039P - First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Presenter: Geoffrey Ku
Session: Poster session 19
1040P - Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours
Presenter: Yasutoshi Kuboki
Session: Poster session 19
1041P - Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
Presenter: Ben Markman
Session: Poster session 19
1042P - INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
Presenter: Akin Atmaca
Session: Poster session 19
1043P - First-in-human study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
Presenter: Do-Youn Oh
Session: Poster session 19
1044P - A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
Presenter: Jun Zhang
Session: Poster session 19
1045P - Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
Presenter: Ravit Geva
Session: Poster session 19
1046P - Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
Presenter: Jung Yong Hong
Session: Poster session 19